In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

BACKGROUND: Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ocio, Enrique M., Vilanova, David, Atadja, Peter, Maiso, Patricia, Crusoe, Edvan, Fernández-Lázaro, Diego, Garayoa, Mercedes, San-Segundo, Laura, Hernández-Iglesias, Teresa, de Álava, Enrique, Shao, Wenlin, Yao, Yung-Mae, Pandiella, Atanasio, San-Miguel, Jesús F.
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2010
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864386/
https://ncbi.nlm.nih.gov/pubmed/19951978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.015495
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы